

396 Views | 43 CrossRef citations to date | 6 Altmetric

Articles

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009

M Neovius , A Sundström, JF Simard, B Wettermark, T Cars, N Feltelius, ... [show all](#)

Pages 8-15 | Accepted 13 May 2010, Published online: 18 Oct 2010

 Cite this article <https://doi.org/10.3109/03009742.2010.493895>

Sample our
Medicine, Dentistry, Nursing
& Allied Health Journals
>> [Sign in here](#) to start your access
to the latest two volumes for 14 days

 Full Article  Figures & data  References  Citations  Metrics

 Reprints & Permissions

[Read this article](#)

 Share

Abstract

Objective: To measure small-area variations in sales per capita of tumour necrosis factor (TNF) inhibitors.

Methods: For 2000–2009, sales data on etanercept, infliximab, and adalimumab were retrieved from the Swedish National Corporation of Pharmacies, which keeps data on drugs dispensed in ambulatory care and hospitals. As points of reference, data were retrieved on all drugs, non-biologic treatments for chronic inflammatory disorders (sulfasalazine, methotrexate, azathioprine), and for a biologic used in a different therapeutic area (trastuzumab). As a corollary measure to sales per capita, penetration

of biologics in the rheumatoid arthritis (RA) population was calculated using nationwide registers. Small areas were defined as the 21 counties of Sweden.

Results: From 2000 to 2009, annual TNF inhibitor sales increased 9-fold from 195 to 1779 million SEK (0.7–5.0% of total drug expenditure). The county variation in sales per capita, initially 6.2-fold (coefficient of variation 42%), decreased to 2.3-fold in 2009 (24%). During the same period, total drug expenditure per capita remained at a 1.2-fold county variation (4–6%). Sales per capita variations of non-biologic treatments against chronic inflammatory diseases ranged from 1.5 to 1.8 (12–16%). For trastuzumab, a 3.2-fold variation (30%) was observed in 2009. At the patient level, there was a 2-fold county variation (from 10% to 21%) in biologic penetration in RA. County-specific sales per capita were associated with mean RA duration ($r = -0.52$, $p = 0.015$) and C-reactive protein at treatment initiation ($r = -0.49$, $p = 0.025$), while pain was borderline significant ($r = -0.43$, $p = 0.055$).

Conclusions: Despite universal access to treatment, substantial but decreasing small-area variations were observed. Although geographic variations are anticipated initially, their persistence calls for investigation of patient equity and treatment appropriateness as counties seem to have different initiation thresholds.

Acknowledgements

We thank Anna Lindhé, Västra Götalandsregionen, and Maj Carlsson, Region Skåne, for providing data on the allocation of county sales of TNF inhibitors by indication.

The ARTIS Study Group conducts scientific analyses using data from the Swedish Biologics Register ARTIS run by the Swedish Society for Rheumatology. For the maintenance of this register, the Swedish Society for Rheumatology has received funding, independent of the conduct of these scientific analyses, from Schering-Plough, BMS, Wyeth, Abbott Laboratories, and Roche.

The ARTIS Study Group (in alphabetical order): E Baecklund (Uppsala University), L Cöster (Linköping University), C Dackhammar (Sahlgrenska Academy), N Feltelius (Medical Products Agency), P Geborek (Lund University), L Jacobsson (Lund University), L Klareskog (Karolinska Institutet), S Lindblad (Karolinska Institutet), S Rantapaa-

Related Research Data

[Small-Area Variations in the Use of Common Surgical Procedures: An International Comparison of New England, England, and Norway](#)

Source: New England Journal of Medicine

[A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness](#)

Source: Health Technology Assessment

[The Application of Statistics as an Aid in Maintaining Quality of a Manufactured Product](#)

Source: Journal of the American Statistical Association

[Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden](#)

Source: Health Policy

[Individual and collective bodies: using measures of variance and association in contextual epidemiology](#)

Source: Journal of Epidemiology & Community Health



Related research

People also read

Recommended articles

Cited by
43

Information for

[Authors](#)

[R&D professionals](#)

[Editors](#)

[Librarians](#)

[Societies](#)

Opportunities

[Reprints and e-prints](#)

[Advertising solutions](#)

[Accelerated publication](#)

[Corporate access solutions](#)

Open access

[Overview](#)

[Open journals](#)

[Open Select](#)

[Dove Medical Press](#)

[F1000Research](#)

Help and information

[Help and contact](#)

[Newsroom](#)

[All journals](#)

[Books](#)

Keep up to date

Register to receive personalised research and resources by email



Sign me up



Copyright © 2026 Informa UK Limited [Privacy policy](#)

[Cookies](#) [Terms & conditions](#) [Accessibility](#)

Registered in England & Wales No. 01072954
5 Howick Place | London | SW1P 1WG

 Taylor and Francis
Group